Pembrolizumab trials for Unresectable Triple-Negative Breast Carcinoma

Q: How many trials study Pembrolizumab for Unresectable Triple-Negative Breast Carcinoma?

4 recruiting trials study Pembrolizumab in trials listing Unresectable Triple-Negative Breast Carcinoma in our tracked data. This is not a statement that it treats the condition.

All Pembrolizumab trials · All Unresectable Triple-Negative Breast Carcinoma trials

Recruiting trials

Phase breakdown

Phase 1 3Phase 2 2

Recruiting trials studying Pembrolizumab for Unresectable Triple-Negative Breast Carcinoma

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
NCT06324240 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
NCT05741164 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT05422794 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations

Common questions

How many trials study Pembrolizumab for Unresectable Triple-Negative Breast Carcinoma?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.